Melphalan FOCUS



Melphalan FOCUS Melphalan FOCUS PRELIMINARY SCORE **SCORE** CURATIVE **CURATIVE** Overall Survival / Disease-Free Survival / Pathological Complete Response **NON-CURATIVE NON-CURATIVE** Overall Survival **ADJUSTMENTS** Quality of life Progression-Free Survival Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate Serious and disabling adverse effects Overall Response Rate / Duration of Response Overall Survival / Disease-Free Survival / Pathological Complete Response Other adjustments INFORMATION Tumour type: Skin Cancers Therapeutic Indication: A liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation Experimental Arm: Melphalan Control Arm: Single arm



© 2024 | European Society for Medical Oncology | ESMO - MCBS 1.1 | All rights reserved worldwide.